Browsing Tag
Luke Miels
6 posts
GSK’s bepirovirsen wins FDA priority review as chronic hepatitis B strategy enters decisive phase
GSK has FDA momentum in hepatitis B. The harder question is whether bepirovirsen can turn functional cure into a real market shift.
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.
GSK stock jumps as insider Luke Miels named next CEO — can he deliver growth before HIV patent cliff hits?
GSK shares rise after naming Luke Miels as CEO-designate to succeed Emma Walmsley on Jan 1, 2026. Find out what investors expect next.
China’s shingles vaccine landscape revolutionized as GSK partners with Zhifei
Global pharmaceutical titan GSK plc is teaming up with Chongqing Zhifei Biological Products, Ltd. (Zhifei) – China’s leading…
GSK to acquire Canadian biopharma company BELLUS Health for $2bn
GSK has agreed to acquire BELLUS Health, a Canadian biopharma company, in a deal worth around $2 billion…
GSK to acquire US biopharma company Sierra Oncology for $1.9bn
GlaxoSmithKline (GSK) has agreed to acquire Sierra Oncology, a California-based biopharma company, in a deal worth around $1.9…